Sign In
Buy RNA
$11.35
-0.110 (-0.96%)
At Close: Jul 31, 2026
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates
06:21pm, Friday, 09'th Aug 2024
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.66 per share a year ago.
Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights
04:05pm, Friday, 09'th Aug 2024
Avidity reports positive del-zota (AOC 1044) data; demonstrated 25% increase in dystrophin production and reduction of creatine kinase levels to near normal in people living with DMD44 in Phase 1/2 EX
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:15am, Monday, 05'th Aug 2024
SAN DIEGO , Aug. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Co
Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer
09:00am, Monday, 05'th Aug 2024
SAN DIEGO , Aug. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Co
3 Stocks Doing Even Better Than Superstar Super Micro (SMCI)
06:41am, Wednesday, 24'th Jul 2024
With a bull market barely showing signs of slowing down, one of the best outperforming stocks this year is Super Micro Computer (NASDAQ: SMCI ). The premier provider of AI-optimized computers, servers
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
07:00am, Tuesday, 23'rd Jul 2024
Interest rate cuts may could provide a major catalyst for Russell 2000 listed stocks. These three Russell 2000 constituents warrant a serious look by growth investors right now.
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 22'nd Jul 2024
SAN DIEGO , July 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
04:05pm, Monday, 24'th Jun 2024
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that targ
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 21'st Jun 2024
SAN DIEGO , June 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day
09:00am, Thursday, 20'th Jun 2024
FSHD Society to host Avidity webinar on positive initial data from the Phase 1/2 FORTITUDE™ trial for people living with FSHD today at 1:00 p.m. ET SAN DIEGO , June 20, 2024 /PRNewswire/ -- Avidity
SAN DIEGO , June 17, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
Avidity Biosciences to Participate in Upcoming Investor Conference
09:00am, Friday, 14'th Jun 2024
SAN DIEGO , June 14, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock
08:00pm, Thursday, 13'th Jun 2024
SAN DIEGO , June 13, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
12:04pm, Thursday, 13'th Jun 2024
Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
04:01pm, Wednesday, 12'th Jun 2024
SAN DIEGO , June 12, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
